Date of preparation:	19 April 2024
Issuer's abbreviated name:	SYNEKTIK SA
Current report:	24/2024 ESPI
Subject:	Contract for the exclusive distribution of Qure.ai's global artificial intelligence solution to assess the results of radiology tests in Poland, the Czech Republic and Slovakia
Legal basis:	Article 17 Section 1 of MAR – confidential information

Body of the report:

Time of publication: 7:58 a.m.

The Management Board of Synektik SA ("Company") reports that on 18 April 2024 a contract was concluded by whose power the Company has become the sole distributor in Poland, the Czech Republic and Slovakia of Qure.ai, a global supplier of artificial intelligence solutions to detect irregularities and assess the results of radiology tests, computed tomography and mammography. The contract was concluded by and between the Company and Mex-Healthcare Sp. z o.o. (hereinafter referred to as the "Licensor") holding the exclusive right to extend licenses to sell Qure.ai's software in selected countries in Europe, the Middle East and Africa. The AI technology in imaging radiology developed by QURE.ai holds class IIb CE certification pursuant to the EU Medical Device Regulation (EU-MDR) and is the most frequently implemented software employing artificial intelligence to analyze and describe the results of x-ray, computed tomography and mammography tests in the world.

Pursuant to the concluded agreement, during the first stage of the project lasting until 30 September 2024, the Company will run a number of tests to verify the possibilities of effectively implementing Qure.ai's artificial intelligence software on a large scale in medical and telemedicine centers. After completing market analysis the Company will have the opportunity to continue the contract on the

agreed terms and conditions or withdraw from it without incurring any legal or economic consequences.

This contract has been concluded for a term of three years starting from 1 October 2024 with an option for the Parties to extend it for another three years.

After completing market analysis, provided that the contract is extended, the Company will be obligated to deliver specified sales results, while if it fails to attain those targets, it will be obligated to remit contractual penalties. The other terms and conditions of the contract do not deviate from the clauses generally used in contracts of this type.

QURE.ai is a global artificial intelligence solutions provider that detects irregularities in various radiology modalities, including mammography, chest and musculoskeletal system x-ray and chest and head computed tomography. This technology enhances the precision and effectiveness of radiology functions in a traditional hospital and in teleradiology companies.

It also makes it possible to diagnose patients more rapidly while enabling physicians and radiologists to segregate medical cases effectively, especially in emergencies or during admissions to the emergency room. This helps health care providers identify critical scenarios within seconds to avoid deaths and enhance the quality of patient care.

At the same time, the Company's Management Board reports that the Qure.ai technology will be used to develop the function of the proprietary platform Zbadani.pl, where the conclusion of this contract regarding the distribution of solutions predicated on artificial intelligence used to assess radiology tests, computed tomography and mammography is a continuation of the growth strategy pursued by the Company and the Group in this area. According to the Company's Management Board the distribution of systems based on artificial intelligence may prospectively have a significant positive impact on the Company's results.

Persons representing the Issuer:

Cezary Kozanecki – President of the
  Management Board